MapLight Therapeutics, Inc. (MPLT)
NASDAQ: MPLT · Real-Time Price · USD
33.28
+1.32 (4.13%)
At close: Jun 26, 2026, 4:00 PM EDT
32.61
-0.67 (-2.01%)
After-hours: Jun 26, 2026, 5:02 PM EDT
MapLight Therapeutics Earnings Call Transcripts
Fiscal Year 2026
-
ML-004 did not improve social communication in ASD but showed robust, clinically meaningful reductions in irritability among adolescents with moderate to severe symptoms, with effect sizes exceeding current therapies and a favorable safety profile. It was well-tolerated, with no severe adverse events and minimal weight gain or sedation.
-
The company is advancing a CNS pipeline with a focus on circuit-specific therapeutics, highlighting ML-007’s potential for improved tolerability and ease of use over competitors. Key phase II data in schizophrenia and autism are expected in Q3 2024, with strong financial resources supporting progress through 2027.